> very expensive since they cannot scale This approach does scale, but has new safety risks. They aren't genetically modifying each patient's own cells, one p

> very expensive since they cannot scale This approach does scale, but has new safety risks. They aren't genetically modifying each patient's own cells, one patient at a time, but are trying to create a line of generic T-cells that will attack only the B-cells of any patient. The risk is that genetically modified T-cells that are not derived from your own cells might attack all the cells of your body, and not just your misbehaving B-cells. They have made additional modifications to the CAR-T T-cells that they believe will prevent them from going rogue, but more safely testing is needed. From what I've read, this same more generic approach is being attempted with CAR-T cancer treatment as well.